Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CJM112 and PDR001 +/- LCL161 in Relapsed/Refractory Multiple Myeloma
NCT03111992Phase 1Completed
- Sponsor
- Novartis
- Start
- Dec 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of CJM112 and LCL161 in multiple myeloma (MM) (3 arms), sponsored by Novartis. Primary endpoints: Number of patients reporting dose limiting toxicities at 2 months, Number of patients who experience a treatment-related adverse event at 24 months and 3 more. Started Dec 2017; status: completed.
02
Drugs
CJM112LCL161
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03111992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03111992.